{"id":177525,"date":"2026-01-23T09:00:00","date_gmt":"2026-01-23T14:00:00","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=177525"},"modified":"2026-01-26T12:35:56","modified_gmt":"2026-01-26T17:35:56","slug":"laurus-labs-q3-profit-up-174-amid-strong-growth-streak","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/laurus-labs-q3-profit-up-174-amid-strong-growth-streak\/","title":{"rendered":"Laurus Labs: Q3 Profit up 174% Amid Strong Growth Streak"},"content":{"rendered":"\n
Laurus Labs Limited (NSE: LAURUSLABS, BSE: 540222) shares closed at \u20b91,017.15 on Friday, up 1.21% following the release of its third-quarter financial results. The pharmaceutical manufacturer\u2019s shares reached an intraday high of \u20b91,032 before settling higher for the session.<\/p>\n\n\n\n
Market Capitalization<\/h2>\n\n\n\n
The company’s market capitalization stands at approximately \u20b9549.17 billion based on today’s closing price.<\/p>\n\n\n\n
Latest Quarterly Results<\/h2>\n\n\n\n
For the quarter ended December 31, 2025, Laurus Labs reported consolidated revenue from operations of \u20b917.78 billion, a 25.7% increase compared with \u20b914.15 billion in the same period last year. Net profit for the quarter rose 174% to \u20b92.52 billion, up from \u20b9923 million a year ago.<\/p>\n\n\n\n
Synthesis (CDMO): Revenue increased 2% to \u20b94.08 billion.<\/li>\n\n\n\n
Bio: Revenue for the period was \u20b9430 million.<\/li>\n\n\n\n
EBITDA: Reported at \u20b94.85 billion, with margins expanding to 27.3% from 20.1% year-on-year.<\/li>\n<\/ul>\n\n\n\n<\/figure>\n\n\n\n
Full-Year Results Context<\/h2>\n\n\n\n
For the nine months ended December 31, 2025, total revenue reached \u20b950.01 billion, a 30% increase over the previous year. Nine-month EBITDA stood at \u20b913.03 billion, representing a 104% increase. Net debt-to-EBITDA improved to 1.2x from 3.4x in the prior year, indicating a directional trend of deleveraging.<\/p>\n\n\n\n
The company confirmed the operationalization of its high-potent API plant at Unit 2 in Visakhapatnam. In the animal health segment, commercial supplies have commenced following the completion of qualification batches. The company reported a 15% capital expenditure-to-sales ratio for the period, focused on its new manufacturing complex.<\/p>\n\n\n\n
M&A or Strategic Moves<\/h2>\n\n\n\n
Laurus Labs increased its investment in KRKA Pharma India by \u20b9490 million, bringing the total joint venture investment to \u20b91 billion. The company also executed a $2 million strategic investment in Aarvik Therapeutics to access antibody-drug conjugate (ADC) technology. Additionally, a further equity infusion was made into ImmunoACT to support the scaling of CAR-T cell therapy services.<\/p>\n\n\n\n
Equity Analyst Commentary<\/h2>\n\n\n\n
Institutional research from Motilal Oswal and Kotak Institutional Equities noted the recovery in the ARV portfolio and CDMO project execution. Reports from BOB Capital Markets indicated that the Q3 results were ahead of consensus estimates for margins and net income.<\/p>\n\n\n\n
Guidance & Outlook<\/h2>\n\n\n\n
Management stated that the company remains on track to deliver its stated operational growth for the full fiscal year. Key factors to watch include the continued ramp-up of the animal health division and the progression of the eight-year, $600 million investment plan for the Andhra Pradesh manufacturing hub.<\/p>\n\n\n\n
Performance Summary<\/h2>\n\n\n\n
Laurus Labs shares closed 1.21% higher following a 174% increase in quarterly profit. Revenue grew 26% for the quarter and 30% for the nine-month period. Operational improvements were driven by the Generics and CDMO segments, alongside a reduction in the net debt-to-EBITDA ratio.<\/p>\n","protected":false},"excerpt":{"rendered":"
Laurus Labs Limited (NSE: LAURUSLABS, BSE: 540222) shares closed at \u20b91,017.15 on Friday, up 1.21% following the release of its third-quarter financial results. The pharmaceutical manufacturer\u2019s shares reached an intraday high of \u20b91,032 before settling higher for the session. Market Capitalization The company’s market capitalization stands at approximately \u20b9549.17 billion based on today’s closing price. […]<\/p>\n","protected":false},"author":2400,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5747,1941,392,5],"tags":[10169,13743,14711],"class_list":["post-177525","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-stocks","category-stock-analysis","category-earnings","category-latest","tag-earnings","tag-health-care","tag-laurus-labs"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":177358,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q3-fy26-earnings-results\/","url_meta":{"origin":177525,"position":0},"title":"Laurus Labs Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 23, 2026","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Laurus Labs Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":144359,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q4fy23-earnings\/","url_meta":{"origin":177525,"position":1},"title":"Laurus Labs Limited Q4FY23 Earnings","author":"Karan_Singh","date":"April 27, 2023","format":false,"excerpt":"To meet the demands of the international pharmaceutical industry, Laurus Labs primarily provides a comprehensive and integrated portfolio of Active Pharmaceutical Ingredients (API), including intermediates, Generic Finished Dosage Forms (FDF), and Contract Research services. Financial Results: Laurus Labs Ltd. reported Total Income for Q4FY23 of \u20b9 1,382.61 Crores down from\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":139439,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q3-fy23-consolidated-revenue-jumps-by-50\/","url_meta":{"origin":177525,"position":2},"title":"Laurus Labs Limited Q3 FY23; Consolidated Revenue Jumps By 50%","author":"Hardik Bhandare","date":"January 30, 2023","format":false,"excerpt":"Laurus Labs Limited (NSE: LAURUSLABS) reported Revenue from Operations for Q3 FY23 of \u20b91,544.82 Crore up from \u20b91028.76 Crore year on year, a growth of 50%. Consolidated Net Profit of \u20b9277.85 Crore, up 31% from \u20b9154.97 Crore in the same quarter of the previous year. The Earnings per Share is\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166795,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q3fy25-304-rise-in-profits\/","url_meta":{"origin":177525,"position":3},"title":"Laurus Labs Ltd Q3FY25; 304% rise in Profits","author":"Chirag Gupta","date":"February 11, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168672,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q4fy25-211-rise-in-profits\/","url_meta":{"origin":177525,"position":4},"title":"Laurus Labs Ltd Q4FY25; 211% rise in Profits","author":"Chirag Gupta","date":"June 5, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":143078,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q3fy23-net-profit-rises-by-32-percent\/","url_meta":{"origin":177525,"position":5},"title":"Laurus Labs Q3FY23 net profit rises by 32 percent","author":"Chirag Gupta","date":"March 1, 2023","format":false,"excerpt":"Pharmaceutical and biotechnology company Laurus Labs reported 32% year-on-year (YoY) rise in profit after tax to INR 203 crore for the quarter ended December 31, 2022. The company had reported a net profit of INR 155 crore in the same quarter, previous fiscal year. The company's consolidated revenue from operations\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"earnings preview","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2400"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=177525"}],"version-history":[{"count":2,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177525\/revisions"}],"predecessor-version":[{"id":177534,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177525\/revisions\/177534"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=177525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=177525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=177525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Laurus-Labs-performance-1024x555.png\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Laurus-Labs_Quarterly-Revenue-Trend-1024x572.png\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Laurus-Labs_EBITDA-Margin-Trend-1024x572.png\")
<\/figure>\n\n\n\n